Exosome mimetic nanoparticles for siRNA based targeting of α-synuclein and neuroinflammation in Parkinson's disease.
S, S., AP, S., H, S., S, G., D, T., & V, C. (2026). Exosome mimetic nanoparticles for siRNA based targeting of α-synuclein and neuroinflammation in Parkinson's disease.. The Journal of pharmacy and pharmacology. https://doi.org/10.1093/jpp/rgag052
S S, AP S, H S, S G, D T, V C. Exosome mimetic nanoparticles for siRNA based targeting of α-synuclein and neuroinflammation in Parkinson's disease.. The Journal of pharmacy and pharmacology. 2026; doi: 10.1093/jpp/rgag052
S S, AP S, H S, et al. Exosome mimetic nanoparticles for siRNA based targeting of α-synuclein and neuroinflammation in Parkinson's disease.[J]. The Journal of pharmacy and pharmacology. 2026. DOI: 10.1093/jpp/rgag052.
@article{s2026,
author = {Shamim S and Singh AP and Sharma H and Gohri S and Taumar D and Chaudhary V},
title = {Exosome mimetic nanoparticles for siRNA based targeting of α-synuclein and neuroinflammation in Parkinson's disease.},
journal = {The Journal of pharmacy and pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag052},
note = {PMID: 42234812},
}
TY - JOUR AU - Shamim S AU - Singh AP AU - Sharma H AU - Gohri S AU - Taumar D AU - Chaudhary V TI - Exosome mimetic nanoparticles for siRNA based targeting of α-synuclein and neuroinflammation in Parkinson's disease. T2 - The Journal of pharmacy and pharmacology PY - 2026 DO - 10.1093/jpp/rgag052 AN - PMID:42234812 ER -
BACKGROUND: Parkinson's disease (PD) is a neurodegenerative disorder caused by degeneration of dopaminergic neurons and accumulation of α-synuclein protein, leading to sustained neuroinflammation. OBJECTIVE: This review analyze the application of gene silencing mediated by small interfering RNAs for α-synuclein protein and inflammatory factors in the treatment of PD. The use of exosomes-mimetic nanoparticles (EM-NPs) for siRNA delivery will be highlighted in particular. METHODS: This review highlights recent findings on the molecular mechanisms involved in PD, the development of siRNA drugs, and the potential of EM-NP-mediated siRNA delivery systems for CNS delivery. RESULTS: siRNA provides an excellent approach to silence specific disease-related genes, such as SNCA and inflammatory factors. Nevertheless, its practical application is hampered by low stability, enzymatic degradation, difficulty crossing the BBB, and non-specific activity. EM-NPs combine the advantages of biocompatibility and scalability that natural exosomes possess and synthetic nanoparticles exhibit, respectively. CONCLUSION: The delivery of siRNA molecules via EM-NPs could be considered an innovative disease-modifying approach toward treating PD patients, involving both pathological α-synuclein protein and neuroinflammation.